Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Kyverna Therapeutics Names Warner Biddle CEO
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies analyst Michael Yee maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 43.3% and a
Jefferies Remains a Buy on Gilead Sciences (GILD)
This 'Forgotten Child' Is One of the Best Biotech Plays: Analyst